Moreover, we seek to determine the impact of co-targeted PIM and PI3K treatment on mRNA and phosphoprotein expression in prostate cancer cell models and ex vivo cultured prostate cancer tissue, as compared to targeting a single pathway. This evidence concerns the gene PIK3CG and prostate cancer.